Celltrion
Promote the health and welfare of mankind.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $720m | Post IPO Equity |
| Total Funding | 000k | ||
| KRW | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 64 % | 2 % | 21 % | (5 %) | 63 % | 19 % | 20 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 48 % | 51 % | 38 % | 47 % | 31 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 28 % | 30 % | 23 % | 25 % | 12 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 9 % | 7 % | 6 % | 7 % | 6 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Founded in 2002 by Seo Jung-jin, Celltrion is a South Korean biopharmaceutical company that has established a significant presence in the global pharmaceutical market. Seo, who holds degrees in Industrial Engineering and Business Administration, transitioned from roles at Samsung Electro-Mechanics and Daewoo Motors to the bio-industry, founding Celltrion with a vision to enhance global access to critical biologic treatments. His journey involved extensive research across numerous countries to build industry expertise.
Celltrion operates with an integrated business model that covers the entire biopharmaceutical process, from research and development to manufacturing and global distribution. The company's core strategy focuses on the development and production of biosimilars—biologic medical products that are highly similar to already approved reference drugs, offering more affordable treatment alternatives. This approach not only drives revenue through drug sales but also aims to reduce healthcare costs worldwide. Celltrion Healthcare, a related entity, manages the worldwide marketing, sales, and distribution of the medicines developed by Celltrion.
The company's product portfolio centers on monoclonal antibody biosimilars targeting major therapeutic areas like immunology and oncology. A landmark achievement occurred in 2013 when its product Remsima® (a biosimilar of Remicade®) became the world's first biosimilar monoclonal antibody to receive approval from the European Medicines Agency (EMA). This approval was for treating autoimmune diseases, including rheumatoid arthritis and Crohn's disease. Other key products include Truxima®, a biosimilar for blood cancer treatments, and Herzuma®, for certain types of breast and stomach cancer. Beyond biosimilars, Celltrion is actively developing its own novel biologics, including antibody-drug conjugates (ADCs) and multi-specific antibodies, to address unmet medical needs.
Keywords: biopharmaceutical, biosimilars, monoclonal antibodies, Seo Jung-jin, Remsima, Truxima, Herzuma, oncology, autoimmune diseases, drug development, biologic medical products, pharmaceutical manufacturing, Celltrion Healthcare, South Korean biotech, infliximab, rituximab, trastuzumab, antibody-drug conjugates, clinical trials, global distribution
